[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Capricor Therap (CAPR)

Capricor Therap (CAPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,394,521
  • Shares Outstanding, K 57,912
  • Annual Sales, $ 0 K
  • Annual Income, $ -105,040 K
  • EBIT $ -120 M
  • EBITDA $ -118 M
  • 60-Month Beta 0.39
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.49

Options Overview Details

View History
  • Implied Volatility 195.96% (+2.54%)
  • Historical Volatility 69.27%
  • IV Percentile 77%
  • IV Rank 33.84%
  • IV High 456.20% on 12/02/25
  • IV Low 62.85% on 01/22/26
  • Expected Move (DTE 16) 3.36 (13.94%)
  • Put/Call Vol Ratio 0.23
  • Today's Volume 9,198
  • Volume Avg (30-Day) 2,185
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 83,192
  • Open Int (30-Day) 79,890
  • Expected Range 20.72 to 27.44

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.58
  • Number of Estimates 5
  • High Estimate $-0.47
  • Low Estimate $-0.63
  • Prior Year $-0.57
  • Growth Rate Est. (year over year) -1.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.46 +3.28%
on 06/29/26
30.93 -21.66%
on 06/25/26
-4.30 (-15.07%)
since 06/01/26
3-Month
23.46 +3.28%
on 06/29/26
36.82 -34.19%
on 04/20/26
-5.89 (-19.56%)
since 04/01/26
52-Week
4.30 +463.49%
on 11/25/25
40.37 -39.98%
on 12/03/25
+14.53 (+149.79%)
since 07/01/25

Most Recent Stories

More News
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

–Advisory Committee meeting scheduled for July 29, 2026– –Company's Biologics License Application on track with PDUFA target action date of August 22, 2026– SAN DIEGO, June 26, 2026 (GLOBE...

CAPR : 24.23 (+0.62%)
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

Deramiocel demonstrates durable skeletal and cardiac muscle benefit over five years in the HOPE-2 OLE study PUL 2.0 year-over-year decline attenuated to approximately 1 point Findings to be presented...

CAPR : 24.23 (+0.62%)
Capricor Therapeutics to Present at Upcoming Investor Conferences

SAN DIEGO, June 08, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced...

CAPR : 24.23 (+0.62%)
Capricor Therapeutics Q1 Earnings Call Highlights

Capricor Therapeutics (NASDAQ:CAPR) said its Duchenne muscular dystrophy therapy candidate deramiocel remains under active FDA review, while the company is preparing to commercialize the product itself...

CAPR : 24.23 (+0.62%)
Capricor: Q1 Earnings Snapshot

Capricor: Q1 Earnings Snapshot

CAPR : 24.23 (+0.62%)
Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Deramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soon HOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb...

CAPR : 24.23 (+0.62%)
Capricor Therapeutics Faces Pivotal BLA Decision Window but Investors Will Scrutinize Cash Trajectory

Barchart Research What to Expect from CAPR Earnings CAPR Generated May 11, 2026 Current Price $31.90 EPS Estimate $$-0.55 Consensus Rating Strong Buy Average Move 8.56% Capricor Therapeutics Faces Pivotal...

CAPR : 24.23 (+0.62%)
Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12

– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET – SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics  (NASDAQ: CAPR), a biotechnology company developing transformative...

CAPR : 24.23 (+0.62%)
Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting

SAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced...

CAPR : 24.23 (+0.62%)
Capricor: Q4 Earnings Snapshot

Capricor: Q4 Earnings Snapshot

CAPR : 24.23 (+0.62%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based...

See More

Key Turning Points

3rd Resistance Point 25.89
2nd Resistance Point 25.44
1st Resistance Point 24.76
Last Price 24.23
1st Support Level 23.63
2nd Support Level 23.18
3rd Support Level 22.50

See More

52-Week High 40.37
Fibonacci 61.8% 26.59
Last Price 24.23
Fibonacci 50% 22.33
Fibonacci 38.2% 18.08
52-Week Low 4.30

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.